Arlo-cel is named as an intervention in 2 current clinical trials in our USA, Canada, Israel, UK, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore and Australia registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The most-studied condition is Relapsed or Refractory Multiple Myeloma (RRMM).
Mechanism, targets and diseases from ChEMBL via the Open Targets Platform (release 26.09), matched to this page as ChEMBL record CHEMBL6068435. ChEMBL data is licensed CC BY-SA 3.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 3 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel |
|
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | USA, Canada, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Canada, Israel, UK, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore and Australia registers name Arlo-cel (also registered as BMS-986393) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in Canada, 2 with sites in Israel, 1 with sites in UK, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Brazil, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Singapore and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Arlo-cel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Arlo-cel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Arlo-cel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.